Prizes and awards recipients announced
21 July 2019 (Mexico City, Mexico) – The International AIDS Society (IAS) announced recipients of prizes and awards at the 10th IAS Conference on HIV Science (IAS 2019) today. These recognize innovation in HIV research, leadership in protecting human rights and the most promising work by an emerging generation of early-career scientists.
The honourees will take the stage in Mexico City this week in recognition of their contributions to the field.
“We are witnessing an exciting moment in science with incremental breakthroughs each day that take us closer to eliminating HIV,” IAS 2019 International Scientific Chair and IAS President Anton Pozniak said. “These awards provide the opportunity to recognize the tireless contributions of established researchers and to welcome the next generation into the fold.”
The following recipients of prizes and awards at IAS 2019 were announced.
Research
awards
Lange/van Tongeren Prizes
(IAS-ANRS) for Young Investigators
The US$2,000
Lange/van Tongeren Prizes for Young Investigators, named in
memory of Joep Lange and Jacqueline van Tongeren, are
jointly funded by the IAS and the Agence Nationale de
Recherche sur le sida et les hépatites virales (ANRS). The
prizes support young researchers who demonstrate innovation,
originality, rationale and quality in the field of HIV
research. One prize is awarded to the top-scoring abstracts
in each of the conference tracks. The Lange/van Tongeren
Prizes for Young Investigators at IAS 2019 are awarded
to:
Track A: Basic science
• Stéphane Isnard
(Canada), “Relevance of Reg3 and I-FABP on microbial
translocation, inflammation and reservoir size in people
living with HIV”
Track B: Clinical science
• Faith Moyo (South Africa), “Characterizing viral
load burden among HIV-infected women at time of delivery:
Findings from four tertiary obstetric units in Gauteng,
South Africa”
Track C: Prevention science
• Matthew A. Spinelli (United States), “Homelessness
at diagnosis is the strongest predictor of death among
persons with HIV in a population-based study of a U.S.
city”
Track D: Implementation science
• Carrie
Lyons (United States), “Utilizing individual level data to
characterize the relationship between HIV infection and the
legal context of sex work across 10 countries in sub Saharan
Africa”
Presented by François Dabis, Director, ANRS,
France, and Anton Pozniak, IAS 2019 International Scientific
Chair and IAS President, Chelsea and Westminster Hospital
NHS Trust, United Kingdom.
IAS/Abivax
Research-for-Cure Academy Fellowship Prize
The
IAS Research-for-Cure Academy provides training on
state-of-the-art HIV cure research to talented early- to
mid-career investigators and clinical scientists working in
resource-constrained settings. This US$2,000 annual prize is
presented to a member of the academy class whose work shows
particular promise. The second annual Research-for-Cure
Academy Fellowship Prize is awarded to:
• Natalia
Laufer (Argentina), for her active engagement and valuable
input to the collaborative research projects at the
Research-for-Cure Academy. Natalia works as a as a
physician, basic/clinical researcher, teacher and as a
member of a community outreach programme. Find out more.
Presented by Sharon
Lewin, The Doherty Institute, The University of Melbourne,
Australia, and Ian McGowan, Orion Biotechnology, Spain.
IAS TB/HIV Research Prizes
The five
US$2,000 IAS TB/HIV Research Prizes are awarded by the IAS
HIV Co-Infections and Co-Morbidities initiative. The prizes
incentivize the investigation of pertinent research
questions that affect TB/HIV co-infection and operational
effectiveness of implementing core TB/HIV collaborative
services, including TB/HIV service integration research. The
prizes are presented to the five top-scoring abstracts in
any of these areas. The IAS TB/HIV Research Prizes at IAS
2019 are awarded to:
• Nathalie De Castro (France),
“Virologic efficacy of raltegravir vs. efavirenz-based
antiretroviral treatment in HIV1-infected adults with
tuberculosis: W48 results of the ANRS 12300 Reflate TB2
trial”
• Justin Jones (United States),
“Community-based case finding for tuberculosis & HIV
integrated with non-communicable diseases in KwaZulu-Natal,
South Africa”
• Leila Chaisson (United States),
“CD4 count-based guidelines for tuberculin skin testing
and tuberculosis preventive therapy in people living with
HIV”
• Jennifer Zelnick (United States), “Severe
adherence challenges in the treatment of multi- and
extensively drug resistant tuberculosis and HIV: Electronic
dose monitoring and mixed methods to identify and
characterize high-risk subpopulations”
• Anna Maria
Mandalakas (United States), “ART initiation within 8 weeks
of TB treatment leads to superior TB outcomes in ART-naïve
children and adolescents living with HIV: Results from six
high TB/HIV burden countries”
Presented by Juan
Mosqueda, Universidad de Guanajuato, Mexico, and Cristina
Mussini, University of Modena and Reggio Emilia, Italy.
IAS Injecting Drug Use Research Prizes
The five inaugural US$2,000 IAS Injecting Drug
Use Research Prizes are awarded by the IAS HIV Co-Infections
and Co-Morbidities initiative. The prizes incentivize
researchers to address important questions around the
management of HCV infection and/or HIV/HCV co-infection in
people who inject drugs, in particular through
interdisciplinary research on drug dependence, harm
reduction and/or drug policy. The IAS Injecting Drug Use
Research Prizes at IAS 2019 are awarded to:
• Pieter
Baker (United States), “Policing as a structural
determinant of HIV risk among people who inject drugs: A
systematic literature review”
• Maria Luisa Mittal
(Mexico), “Gender differences in syringe-related policing
behaviors and attitudes following a police education program
in Tijuana, Mexico: A longitudinal mixed methods
analysis”
• Olga Denisiuk (Ukraine), “Community
initiated treatment for HIV-positive people who inject drugs
in Ukraine”
• Sun Tun (Myanmar), “Heroin use and
sexual risk behaviours among HIV/HCV co-infected methadone
patients in Myanmar”
• Elia Mmbaga (Tanzania),
“HCV, HIV/HCV co-infection among people injecting drugs in
Tanzania: A hidden epidemic”
Presented by Rayner Kay
Jin Tan, National University of Singapore, Singapore, and
Olga Varetska, Alliance for Public Health,
Ukraine.
Dominique Dormont
Award
The US$5,000 IAS and ANRS Dominique
Dormont award is funded by the Dominique Dormont Association
to support young researchers working on chronic conditions,
with a particular focus on the interface between HIV and
other chronic diseases. The prize highlights researchers who
demonstrate originality, rationale, quality and a
multidisciplinary and integrative approach in the field of
HIV and AIDS research. The IAS-ANRS Dominique Prize at IAS
2019 is awarded to:
• Stéphane Isnard (Canada),
“Relevance of Reg3 and I-FABP on microbial
translocation, inflammation and reservoir size in people
living with HIV”
Presented by Michaela Muller-Trutwin,
Institut Pasteur, France.
IAS CIPHER Research
Grants
CIPHER is the IAS Collaborative
Initiative for Paediatric HIV Education and Research. The
CIPHER Grants provide a unique opportunity for early-stage
investigators to address targeted research gaps in
paediatric and adolescent HIV in resource-limited settings
that support evidence-informed policy. The grants are for up
to US$150,000 each for up to two years, and 80% of grants
awarded go to applicants from low- and middle-income
countries. The grants are made possible through support from
CIPHER founding sponsor ViiV Healthcare and Janssen. The
2019 CIPHER Research Grants are presented to:
• Ceri
Evans (Zimbabwe), whose project will evaluate the impact of
improved water, sanitation and hygiene (WASH) on
cytomegalovirus co-infection in HIV-affected mothers and
children in rural Zimbabwe
• Tongdiyen Jasper
(Nigeria), who will investigate the impact of structured
caregiver peer support (CaPS) on ART adherence and viral
suppression among children living with HIV in Nigeria in a
randomized controlled trial
• Sarah Skeen (South
Africa), for the Khwezi Lokusa (Early Morning Star) Project,
which will look at integrating an evidence-based
intervention component to promote HIV testing of young
children into community-based parenting programmes
In addition, one young researcher was selected to
receive a CIPHER Fellowship contributing to strengthened HIV
clinical research capacity in countries with high HIV
burden.
• Janan Dietrich (South Africa), who will
investigate factors associated with viral suppression among
adolescent girls and young women living with HIV and
participating in the HERStory Study in six South African
districts
Presented by Anton Pozniak, IAS 2019
International Scientific Chair and IAS President, Chelsea
and Westminster Hospital NHS Trust, United
Kingdom.
IAS/MSD Prize for Operational and
Implementation Research in Differentiated Service
Delivery
The IAS and Merck Sharpe & Dohme (MSD)
award a co-partnered prize for the top-scoring abstracts in
operational and implementation research in differentiated
service delivery. The prize recognizes outstanding research
that addresses key knowledge gaps and links new evidence to
strategic programme priorities in differentiated service
delivery. The prize (US$10,000 per recipient), funded by
MSD, is awarded to the four highest-scoring abstracts:.
• Jennifer Zech (United States), “Optimizing
treatment models for people living with HIV in urban
Zimbabwe: Findings from a mixed methods
study”
• Vivian Chitiyo (Zimbabwe), “Differentiated
antiretroviral therapy delivery: A review of implementation
progress and challenges in Zimbabwe”
• Didier Kamerhe
(Democratic Republic of the Congo), “Improved HIV
treatment retention among patients enrolled in a
differentiated care model at Kenya General Reference
Hospital in Haut Katanga province of the Democratic Republic
of the Congo”
• Bruce Agins (United States),
“Improving rapid ART initiation in Blantyre, Malawi,
through implementation of a quality improvement
collaborative”
Presented by Linda-Gail Bekker, IAS Past-President, Desmond Tutu HIV Centre, University of Cape Town, South Africa.
“The IAS and its partners
congratulate this diverse pool of researchers,”
Anton Pozniak said. “Their innovation and
dedication to science is both the backbone and future
success of the HIV
response.”